Loading...
Market
What will be BioNTech's strategic move regarding COVID-19 vaccine technology in 2025?
2
Resolution / Starting Odds
Expansion of vaccine production • 25%
New partnership in vaccine development • 25%
Investment in new vaccine technology • 25%
No significant strategic move • 25%
Press releases from BioNTech or official announcements
Story
BioNTech Settles COVID-19 Vaccine Royalties, Paying $791.5M to NIH and $467M to UPenn
Dec 27, 2024, 02:00 PM
BioNTech has reached two separate settlement agreements concerning royalty payments related to its COVID-19 vaccine. The company will pay $791.5 million to the U.S. National Institutes of Health (NIH) and $467 million to the University of Pennsylvania. These agreements were confirmed by BioNTech in recent filings. The settlements address disputes over whether royalties were owed based on the locations where the licensed products were manufactured and sold. Despite these settlements, BioNTech will retain license rights under certain patents held by the University of Pennsylvania.
View original story
Similar markets
Cancer • 25%
Other • 25%
Influenza • 25%
HIV • 25%
Pfizer • 25%
Other • 25%
GlaxoSmithKline • 25%
AstraZeneca • 25%
Focus on other areas • 25%
Focus on both equally • 25%
Focus on genetic engineering • 25%
Focus on cancer treatments • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
13% - 15% • 25%
Above 18% • 25%
10% - 12% • 25%
16% - 18% • 25%
No change • 25%
Looser vaccine mandates • 25%
Stricter vaccine mandates • 25%
Other changes • 25%
No countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
More than 10 countries • 25%
Unclear • 25%
More restrictive • 25%
Less restrictive • 25%
No change • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Decrease • 25%
Increase by less than 10% • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
